

Lawrence A Solberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2179355/publications.pdf>

Version: 2024-02-01

42
papers

5,216
citations

331259

21
h-index

301761

39
g-index

43
all docs

43
docs citations

43
times ranked

4203
citing authors

#	ARTICLE	IF	CITATIONS
1	The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i> , 2011, 117, 4190-4207.	0.6	1,608
2	Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. <i>Nature</i> , 1994, 369, 533-538.	13.7	1,329
3	Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. <i>Leukemia</i> , 2008, 22, 437-438.	3.3	443
4	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006, 108, 1497-1503.	0.6	317
5	Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). <i>Leukemia Research</i> , 2007, 31, 737-740.	0.4	288
6	Anagrelide: A New Drug for Treating Thrombocytosis. <i>New England Journal of Medicine</i> , 1988, 318, 1292-1294.	13.9	170
7	The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. <i>Blood</i> , 2013, 122, 3879-3883.	0.6	159
8	A clinical update in polycythemia vera and essential thrombocythemia. <i>American Journal of Medicine</i> , 2000, 109, 141-149.	0.6	115
9	Anagrelide as a New Platelet-Lowering Agent in Essential Thrombocythemia: Mechanism of Action, Efficacy, Toxicity, Current Indications. <i>Seminars in Thrombosis and Hemostasis</i> , 1997, 23, 379-383.	1.5	75
10	Brain and Cerebrospinal Fluid Permeability to Intravenous Thyroid Hormones*. <i>Endocrinology</i> , 1974, 95, 1398-1410.	1.4	74
11	Disparities in participation in cancer clinical trials in the United States. <i>Cancer</i> , 2008, 112, 447-454.	2.0	70
12	Characterization of human megakaryocytic colony formation in human plasma. <i>Journal of Cellular Physiology</i> , 1985, 124, 67-74.	2.0	63
13	Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. <i>Cancer Genetics and Cytogenetics</i> , 1989, 39, 167-179.	1.0	62
14	Unusual presentation of multiple myeloma with unilateral visual loss and numb chin syndrome in a young adult. <i>American Journal of Hematology</i> , 2002, 70, 55-59.	2.0	47
15	Acute Megakaryocytic Leukemia (M7) in Children. <i>Mayo Clinic Proceedings</i> , 1989, 64, 1339-1351.	1.4	43
16	Myelodysplastic syndromes. <i>Critical Reviews in Oncology/Hematology</i> , 1992, 12, 193-215.	2.0	36
17	Acute Porphyrias: Diagnosis and Management. <i>Mayo Clinic Proceedings</i> , 1994, 69, 991-995.	1.4	31
18	Treatment of thrombotic thrombocytopenic purpura with plasma exchange, antiplatelet agents, corticosteroid, and plasma infusion: Mayo clinic experience. <i>Journal of Clinical Apheresis</i> , 1982, 1, 6-13.	0.7	29

#	ARTICLE	IF	CITATIONS
19	The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. Hematology American Society of Hematology Education Program, 2013, 2013, 9-14.	0.9	29
20	Prognostic Significance of Computed Tomography of the Brain in Thrombotic Thrombocytopenic Purpura. Mayo Clinic Proceedings, 1991, 66, 602-607.	1.4	25
21	Veno-occlusive Disease of the Liver after Blood and Marrow Transplantation: Analysis of Pre- and Post-transplant Risk Factors Associated with Severity and Results of Therapy with Tissue Plasminogen Activator. Leukemia and Lymphoma, 2002, 43, 2099-2107.	0.6	21
22	Hemopoietic colony growth-promoting activities in the plasma of bone marrow transplant recipients.. Journal of Clinical Investigation, 1988, 82, 255-261.	3.9	21
23	Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion, 2008, 48, 1106-1114.	0.8	20
24	Porphyrias: Clinical Evaluation and Interpretation of Laboratory Tests. Mayo Clinic Proceedings, 1994, 69, 289-290.	1.4	17
25	Refractory and Relapsing Multiple Myeloma Treated by Blood Stem Cell Transplantation. American Journal of the Medical Sciences, 1995, 309, 152-161.	0.4	17
26	Therapeutic options for essential thrombocythemia and polycythemia vera. Seminars in Oncology, 2002, 29, 10-15.	0.8	16
27	Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT 3 regimen and literature review. Supportive Care in Cancer, 1999, 7, 413-424.	1.0	14
28	Audit of Nutrition Support for Hematopoietic Stem Cell Transplantation at a Single Institution. Mayo Clinic Proceedings, 2002, 77, 654-659.	1.4	13
29	Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent. Transfusion, 2012, 52, 542-548.	0.8	12
30	Biologic aspects of thrombopoietins and the development of therapeutic agents. Psychophysiology, 2005, 4, 423-8.	1.1	12
31	Molecular analysis of intravascular large B-cell lymphoma with neoangiogenesis. British Journal of Haematology, 2011, 152, 234-236.	1.2	10
32	A New Murine Monoclonal Antibody for the Diagnosis of Erythroleukemia. American Journal of Clinical Pathology, 1990, 93, 387-390.	0.4	6
33	StemCells: A Quarter Century of Progress. Stem Cells, 2007, 25, 1-1.	1.4	6
34	Continuous Infusion Etoposide/Carboplatin for Treatment of Refractory Acute Leukemia. American Journal of Clinical Oncology: Cancer Clinical Trials, 1995, 18, 382-384.	0.6	5
35	A biological and computational model of megakaryocyte development as a stochastic branching process. International Journal of Cell Cloning, 1990, 8, 283-290.	1.6	3
36	Mayo Clinic Experience With Allogeneic and Syngeneic Bone Marrow Transplantation, 1982 Through 1990. Mayo Clinic Proceedings, 1992, 67, 109-116.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Physiology of myeloproliferation. <i>Seminars in Hematology</i> , 2001, 38, 5-9.	1.8	2
38	Proliferation and Maturation of Human Megakaryocytes in Vitro. <i>Annals of the New York Academy of Sciences</i> , 1987, 509, 34-40.	1.8	1
39	Robert A. Kyle: An Appreciation. <i>Oncologist</i> , 2001, 6, 118-118.	1.9	0
40	Increased Incidence of Loco-Regional Recurrences among African American Women with Terminal Stage Breast Cancer. <i>Clinical Medicine Oncology</i> , 2008, 2, CMO.S988.	0.2	0
41	Patients, hematologists, and time. <i>Blood</i> , 2011, 117, 2753-2754.	0.6	0
42	“Kilroy was here” plus!. <i>Oncologist</i> , 2011, 16, 1345-1346.	1.9	0